Innate immune responses against Epstein Barr virus infection

Journal of Leukocyte Biology

Volumn 94, Issue 6, 2013, Pages 1185-1190

  Chijioke, Obinna ^a   Azzi, Tarik ^b   Nadal, David ^b   Münz, Christian ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

B cells; Dendritic cells; Infectious mononucleosis; Natural killer cells; Toll like receptor

Indexed keywords

B LYMPHOCYTE; CANCER RISK; DENDRITIC CELL; EPSTEIN BARR VIRUS INFECTION; HUMAN; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY;

B CELLS; DENDRITIC CELLS; INFECTIOUS MONONUCLEOSIS; NATURAL KILLER CELLS; TOLL-LIKE RECEPTOR;

B-LYMPHOCYTES; DENDRITIC CELLS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; T-LYMPHOCYTES;

EID: 84888785809     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0313173     Document Type: Review

References (69)

1. Epstein, M. A., Achong, B. G., Barr, Y. M. (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1, 702-703.
2. Luzuriaga, K., Sullivan, J. L. (2010) Infectious mononucleosis. N. Engl. J. Med. 362, 1993-2000.
3. Kutok, J. L., Wang, F. (2006) Spectrum of Epstein-Barr virus-associated diseases. Annu. Rev. Pathol. 1, 375-404.
4. Balfour H. H., Jr., Odumade, O. A., Schmeling, D. O., Mullan, B. D., Ed, J. A., Knight, J. A., Vezina, H. E., Thomas, W., Hogquist, K. A. (2013) Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J. Infect. Dis. 207, 80-88.
5. Hislop, A. D., Taylor, G. S., Sauce, D., Rickinson, A. B. (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25, 587-617.
6. Hjalgrim, H., Askling, J., Rostgaard, K., Hamilton-Dutoit, S., Frisch, M., Zhang, J. S., Madsen, M., Rosdahl, N., Konradsen, H. B., Storm, H. H., Melbye, M. (2003) Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N. Engl. J. Med. 349, 1324-1332.
7. Hjalgrim, H., Smedby, K. E., Rostgaard, K., Molin, D., Hamilton-Dutoit, S., Chang, E. T., Ralfkiaer, E., Sundstrom, C., Adami, H. O., Glimelius, B., Melbye, M. (2007) Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 67, 2382-2388.
8. Handel, A. E., Williamson, A. J., Disanto, G., Handunnetthi, L., Giovannoni, G., Ramagopalan, S. V. (2010) An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 5, pii: e12496.
9. Thacker, E. L., Mirzaei, F., Ascherio, A. (2006) Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59, 499-503.
10. Okano, M., Gross, T. G. (1996) Epstein-Barr virus-associated hemophagocytic syndrome and fatal infectious mononucleosis. Am. J. Hematol. 53, 111-115.
11. Rowe, M., Kelly, G. L., Bell, A. I., Rickinson, A. B. (2009) Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin. Cancer Biol. 19, 377-388.
12. Bornkamm, G. W. (2009) Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Int. J. Cancer 124, 1745-1755.
13. Küppers, R. (2012) New insights in the biology of Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2012, 328-334.
14. Knowles, D. M. (1999) Immunodeficiency-associated lymphoproliferative disorders. Mod. Pathol. 12, 200-217.
15. Diebold, J., Raphael, M., Prevot, S., Audouin, J. (1997) Lymphomas associated with HIV infection. Cancer Surv. 30, 263-293.
16. McClain, K. L., Leach, C. T., Jenson, H. B., Joshi, V. V., Pollock, B. H., Parmley, R. T., DiCarlo, F. J., Chadwick, E. G., Murphy, S. B. (1995) Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N. Engl. J. Med. 332, 12-18.
17. Parolini, S., Bottino, C., Falco, M., Augugliaro, R., Giliani, S., Franceschini, R., Ochs, H. D., Wolf, H., Bonnefoy, J. Y., Biassoni, R., Moretta, L., Notarangelo, L. D., Moretta, A. (2000) X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill EpsteinBarr virus-infected cells. J. Exp. Med. 192, 337-346.
18. Bottino, C., Falco, M., Parolini, S., Marcenaro, E., Augugliaro, R., Sivori, S., Landi, E., Biassoni, R., Notarangelo, L. D., Moretta, L., Moretta, A. (2001) NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J. Exp. Med. 194, 235-246.
19. Hislop, A. D., Palendira, U., Leese, A. M., Arkwright, P. D., Rohrlich, P. S., Tangye, S. G., Gaspar, H. B., Lankester, A. C., Moretta, A., Rickinson, A. B. (2010) Impaired Epstein-Barr virus-specific CD8 T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 116, 3249-3257.
20. Palendira, U., Low, C., Chan, A., Hislop, A. D., Ho, E., Phan, T. G., Deenick, E., Cook, M. C., Riminton, D. S., Choo, S., Loh, R., Alvaro, F., Booth, C., Gaspar, H. B., Moretta, A., Khanna, R., Rickinson, A. B., Tangye, S. G. (2011) Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol. 9, e1001187.
21. Jones, J. F., Shurin, S., Abramowsky, C., Tubbs, R. R., Sciotto, C. G., Wahl, R., Sands, J., Gottman, D., Katz, B. Z., Sklar, J. (1988) T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N. Engl. J. Med. 318, 733-741.
22. Kawa-Ha, K., Ishihara, S., Ninomiya, T., Yumura-Yagi, K., Hara, J., Murayama, F., Tawa, A., Hirai, K. (1989) CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J. Clin. Invest. 84, 51-55.
23. Yu, M. C., Yuan, J. M. (2002) Epidemiology of nasopharyngeal carcinoma. Semin. Cancer Biol. 12, 421-429.
24. Shibata, D., Weiss, L. M. (1992) Epstein-Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 140, 769-774.
25. Raab-Traub, N., Flynn, K. (1986) The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47, 883-889.
26. Imai, S., Koizumi, S., Sugiura, M., Tokunaga, M., Uemura, Y., Yamamoto, N., Tanaka, S., Sato, E., Osato, T. (1994) Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc. Natl. Acad. Sci. USA 91, 9131-9135.
27. Kratky, W., Reis e Sousa, C., Oxenius, A., Sporri, R. (2011) Direct activation of antigen-presenting cells is required for CD8 T-cell priming and tumor vaccination. Proc. Natl. Acad. Sci. USA 108, 17414-17419.
28. Casanova, J. L., Abel, L., Quintana-Murci, L. (2011) Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu. Rev. Immunol. 29, 447-491.
29. Gaudreault, E., Fiola, S., Olivier, M., Gosselin, J. (2007) Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J. Virol. 81, 8016-8024.
30. Ariza, M. E., Glaser, R., Kaumaya, P. T., Jones, C., Williams, M. V. (2009) The EBV-encoded dUTPase activates NF-B through the TLR2 and MyD88-dependent signaling pathway. J. Immunol. 182, 851-859.
31. Fiola, S., Gosselin, D., Takada, K., Gosselin, J. (2010) TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J. Immunol. 185, 3620-3631.
32. Martin, H. J., Lee, J. M., Walls, D., Hayward, S. D. (2007) Manipulation of the Toll-like receptor 7 signaling pathway by Epstein-Barr virus. J. Virol. 81, 9748-9758.
33. Younesi, V., Nikzamir, H., Yousefi, M., Khoshnoodi, J., Arjmand, M., Rabbani, H., Shokri, F. (2010) Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B lymphocytes. Microbiol. Immunol. 54, 534-541.
34. Dorner, M., Brandt, S., Tinguely, M., Zucol, F., Bourquin, J. P., Zauner, L., Berger, C., Bernasconi, M., Speck, R. F., Nadal, D. (2009) Plasma cell Toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 128, 573-579.
35. Iwasaki, A., Medzhitov, R. (2004) Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995.
36. Iwakiri, D., Zhou, L., Samanta, M., Matsumoto, M., Ebihara, T., Seya, T., Imai, S., Fujieda, M., Kawa, K., Takada, K. (2009) Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J. Exp. Med. 206, 2091-2099.
37. Lim, W. H., Kireta, S., Russ, G. R., Coates, P. T. (2006) Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood 109, 1043-1050.
38. Woellmer, A., Arteaga-Salas, J. M., Hammerschmidt, W. (2012) BZLF1 governs CpG-methylated chromatin of Epstein-Barr virus reversing epigenetic repression. PLoS Pathog. 8, e1002902.
39. Younesi, V., Shirazi, F. G., Memarian, A., Amanzadeh, A., Jeddi-Tehrani, M., Shokri, F. (2013) Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay. Cytotechnology [Epub ahead of print].
40. Fathallah, I., Parroche, P., Gruffat, H., Zannetti, C., Johansson, H., Yue, J., Manet, E., Tommasino, M., Sylla, B. S., Hasan, U. A. (2010) EBV latent membrane protein 1 is a negative regulator of TLR9. J. Immunol. 185, 6439-6447.
41. Van Gent, M., Griffin, B. D., Berkhoff, E. G., van Leeuwen, D., Boer, I. G., Buisson, M., Hartgers, F. C., Burmeister, W. P., Wiertz, E. J., Ressing, M. E. (2011) EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection. J. Immunol. 186, 1694-1702.
42. Noack, J., Jordi, M., Zauner, L., Alessi, D., Burch, A., Tinguely, M., Hersberger, M., Bernasconi, M., Nadal, D. (2012) TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism. Cell Death Dis. 3, e323.
43. Zauner, L., Melroe, G. T., Sigrist, J. A., Rechsteiner, M. P., Dorner, M., Arnold, M., Berger, C., Bernasconi, M., Schaefer, B. W., Speck, R. F., Nadal, D. (2010) TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. Oncogene 29, 4588-4598.
44. Reizis, B., Bunin, A., Ghosh, H. S., Lewis, K. L., Sisirak, V. (2011) Plasmacytoid dendritic cells: recent progress and open questions. Annu. Rev. Immunol. 29, 163-183.
45. Lotz, M., Tsoukas, C. D., Fong, S., Carson, D. A., Vaughan, J. H. (1985) Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon. Eur. J. Immunol. 15, 520-525.
46. Severa, M., Giacomini, E., Gafa, V., Anastasiadou, E., Rizzo, F., Corazzari, M., Romagnoli, A., Trivedi, P., Fimia, G. M., Coccia, E. M. (2013) EBV stimulates TLR-and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur. J. Immunol. 43, 147-158.
47. Bickham, K., Goodman, K., Paludan, C., Nikiforow, S., Tsang, M. L., Steinman, R. M., Münz, C. (2003) Dendritic cells initiate immune control of Epstein-Barr virus transformation of B lymphocytes in vitro. J. Exp. Med. 198, 1653-1663.
48. Leung, C. S., Maurer, M. A., Meixlsperger, S., Lippmann, A., Cheong, C., Zuo, J., Haigh, T. A., Taylor, G. S., Munz, C. (2013) Robust T cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205. Blood 121, 1584-1594.
49. Münz, C., Bickham, K. L., Subklewe, M., Tsang, M. L., Chahroudi, A., Kurilla, M. G., Zhang, D., O'Donnell, M., Steinman, R. M. (2000) Human CD4 T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191, 1649-1660.
50. Subklewe, M., Paludan, C., Tsang, M. L., Mahnke, K., Steinman, R. M., Münz, C. (2001) Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8 killer T cells. J. Exp. Med. 193, 405-411.
51. Guerreiro-Cacais, A. O., Li, L., Donati, D., Bejarano, M. T., Morgan, A., Masucci, M. G., Hutt-Fletcher, L., Levitsky, V. (2004) Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. J. Gen. Virol. 85, 2767-2778.
52. Trinchieri, G. (1989) Biology of natural killer cells. Adv. Immunol. 47, 187-376.
53. Tomkinson, B. E., Wagner, D. K., Nelson, D. L., Sullivan, J. L. (1987) Activated lymphocytes during acute Epstein-Barr virus infection. J. Immunol. 139, 3802-3807.
54. Hornef, M. W., Wagner, H. J., Kruse, A., Kirchner, H. (1995) Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo. Clin. Diagn. Lab. Immunol. 2, 209-213.
55. Williams, H., McAulay, K., Macsween, K. F., Gallacher, N. J., Higgins, C. D., Harrison, N., Swerdlow, A. J., Crawford, D. H. (2005) The immune response to primary EBV infection: a role for natural killer cells. Br. J. Haematol. 129, 266-274.
56. Zhang, Y., Wallace, D. L., de Lara, C. M., Ghattas, H., Asquith, B., Worth, A., Griffin, G. E., Taylor, G. P., Tough, D. F., Beverley, P. C., Macallan, D. C. (2007) In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121, 258-265.
57. hi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 108, 14725-14732.
58. Bjorkstrom, N. K., Lindgren, T., Stoltz, M., Fauriat, C., Braun, M., Evander, M., Michaelsson, J., Malmberg, K. J., Klingstrom, J., Ahlm, C., Ljunggren, H. G. (2011) Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J. Exp. Med. 208, 13-21.
59. Petitdemange, C., Becquart, P., Wauquier, N., Beziat, V., Debre, P., Leroy, E. M., Vieillard, V. (2011) Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog. 7, e1002268.
60. Shaw, R. K., Issekutz, A. C., Fraser, R., Schmit, P., Morash, B., Monaco-Shawver, L., Orange, J. S., Fernandez, C. V. (2012) Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood 119, 4009-4012.
61. Eidenschenk, C., Dunne, J., Jouanguy, E., Fourlinnie, C., Gineau, L., Bacq, D., McMahon, C., Smith, O., Casanova, J. L., Abel, L., Feighery, C. (2006) A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am. J. Hum. Genet. 78, 721-727.
62. Purtilo, D. T., Yang, J. P., de Girolami, U., Allegra, S. (1975) Letter: Monucleosis-associated subacute sclerosing panencephalitis. Lancet 2, 1310-1311.
63. Sumegi, J., Huang, D., Lanyi, A., Davis, J. D., Seemayer, T. A., Maeda, A., Klein, G., Seri, M., Wakiguchi, H., Purtilo, D. T., Gross, T. G. (2000) Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 96, 3118-3125.
64. Nichols, K. E., Ma, C. S., Cannons, J. L., Schwartzberg, P. L., Tangye, S. G. (2005) Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol. Rev. 203, 180-199.
65. Coffey, A. J., Brooksbank, R. A., Brandau, O., Oohashi, T., Howell, G. R., Bye, J. M., Cahn, A. P., Durham, J., Heath, P., Wray, P., et al. (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 20, 129-135.
66. Pende, D., Rivera, P., Marcenaro, S., Chang, C. C., Biassoni, R., Conte, R., Kubin, M., Cosman, D., Ferrone, S., Moretta, L., Moretta, A. (2002) Major histocompatibility complex class I-related chain a and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62, 6178-6186.
67. Stewart, C. A., Laugier-Anfossi, F., Vely, F., Saulquin, X., Riedmuller, J., Tisserant, A., Gauthier, L., Romagne, F., Ferracci, G., Arosa, F. A., Moretta, A., Sun, P. D., Ugolini, S., Vivier, E. (2005) Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc. Natl. Acad. Sci. USA 102, 13224-13229.
68. Pappworth, I. Y., Wang, E. C., Rowe, M. (2007) The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J. Virol. 81, 474-482.
69. Strowig, T., Brilot, F., Arrey, F., Bougras, G., Thomas, D., Muller, W. A., Münz, C. (2008) Tonsilar natural killer cells restrict B cell transformation by the Epstein Barr virus via IFN. PLoS Pathog. 4, e27.